1. CAS: 120511-73-1
2. Assay: 99.3%
3. MF: C17H19N5
4. MW: 293.37
5. Character: White crystalline powder
6. Usage: An aromatase inhibitor. Used as an antineoplastic raw materials.
Potent selective triazole aromatase inhibitors, can inhibit the cytochrome P-450 aromatase enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast cancer cell growth factors. Treatment of breast cancer, especially for those with hormone relapse after adjuvant therapy after menopause for women with advanced breast cancer.
Specifications:
1kg/aluminium foil bag or as required
Within 24 hours after receiving the payment
Western Union, MoneyGram, T/T
Description:
Arimidex (generic name is anastrozole) is a newer drug developed for the treatment of advanced breast cancer in women. It is manufactured by Zenica Pharmaceuticals and was approved for use in the United States at the end of December 1995. Specifically, Arimidex is the first in a new class of third-generation selective oral aromatase inhibitors.
It acts by blocking the enzyme aromatase, subsequently blocking the production of estrogen. Since many forms of breast cancer cells are stimulated by estrogen, it is hoped that by reducing amounts of estrogen in the body the progression of such a disease can be halted. This is the basic premise behind Nolvadex, except this drug blocks the action and not production of estrogen.
The effects of Arimidex can be quite dramatic to say the least. A daily dose of one tablet (1 mg) can produce estrogen suppression greater than 80 % in treated patients. With the powerful effect this drug has on hormone levels, it is only to be used (clinically) by post-menopausal women whose disease has progressed following treatment with Nolvadex (tamoxifen citrate). Side effects like hot flushes and hair thinning can be present, and would no doubt be much more severe in pre-menopausal patients.
There are some concerns with using an aromatase inhibitor such as this during prolonged steroid treatment however. While it will effectively reduce estrogenic side effects, it will also block the beneficial properties of estrogen from becoming apparent (namely its effect on cholesterol values). Studies have clearly shown that when an aromatase inhibitor is used in conjunction with a steroid such as testosterone, suppression of HDL (good) cholesterol becomes much more pronounced.
Apparently estrogen plays a role in minimizing the negative impact of steroid use. Since the estrogen receptor antagonist Nolvadex is shown not to display an anti-estrogenic effect on cholesterol values, it is certainly the preferred from of estrogen maintenance for those concerned with cardiovascular health.
Applications:
A single tablet daily (1 mg), the same dose use clinically, seems to be all one needs for an exceptional effect (some even report excellent results with only 0.25 mg daily). When used with strong, readily aromatizing androgens such as Dianabol or testosterone, gynecomastia and water retention can be effectively blocked.
In combination with Propecia (finasteride), we have a great advance. With the one drug halting estrogen conversion and the other blocking 5-alpha reduction , related side effects can be effectively minimized. Here the strong androgen testosterone could theoretically provide incredible muscular growth, while at the same time being as tolerable as nandrolone.
Additionally the quality of the muscle should be greater, the athlete appearing harder and much more defined without holding excess water.
:
Tel:00862781331422
Fax:00862781331422
Cel:+8615337164625/+8613294170285
Skyepe:leslie@carphetin.com
Email:leslie@carphetin.com
关键字： Anastrozole ；Arimidex ；
武汉卡非林化工有限公司公司位于美丽的武汉市江夏区，是中部地区大型的专业从事精细化工，医药原料，中间体,香精香料及食品添加剂，等产品的研发，生产，销售于一体的高科技化工企业。卡非林（carphetin）制定有质量诚信手册及与GMP相配套的各类程序文件，成立有QA、QC为主体的质量诚信管理系统，为满足客户对产品的各种需求提供了坚实的保证。
卡非林（carphetin）与多个高校，世界各大化工医药原材料供应商保持着长久良好的合作关系，公司拥有自主进出口经营权,产品远销欧美，东南亚等30多个国家和地区并深受客户的好评。今天，卡非林（carphetin）提供超过2000多种种产品的库存，包装大小从克级到大包装规格，也包括部分半散装和散装产品。